Universe Pharmaceuticals (UPC) Debt to Equity (2021 - 2025)
Universe Pharmaceuticals' Debt to Equity history spans 4 years, with the latest figure at $175.69 for Q3 2024.
- For Q3 2024, Debt to Equity rose 89630121.25% year-over-year to $175.69; the TTM value through Sep 2024 reached $175.69, up 89630121.25%, while the annual FY2024 figure was $175.69, 89630121.25% up from the prior year.
- Debt to Equity for Q3 2024 was $175.69 at Universe Pharmaceuticals, up from $0.0 in the prior quarter.
- Across five years, Debt to Equity topped out at $175.69 in Q3 2024 and bottomed at $0.0 in Q3 2022.
- The 4-year median for Debt to Equity is $0.0 (2021), against an average of $43.92.
- The largest annual shift saw Debt to Equity crashed 77.21% in 2022 before it surged 89630121.25% in 2024.
- A 4-year view of Debt to Equity shows it stood at $0.0 in 2021, then tumbled by 77.21% to $0.0 in 2022, then soared by 104.93% to $0.0 in 2023, then skyrocketed by 89630121.25% to $175.69 in 2024.
- Per Business Quant, the three most recent readings for UPC's Debt to Equity are $175.69 (Q3 2024), $0.0 (Q3 2023), and $0.0 (Q3 2022).